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Loss of Nrf2 abrogates the 
protective effect of Keap1 
downregulation in a preclinical 
model of cutaneous squamous  
cell carcinoma
Elena V. Knatko1, Maureen Higgins1, Jed W. Fahey2,3,4 & Albena T. Dinkova-Kostova1,2,4
Cutaneous squamous cell carcinomas (cSCC) are the most common and highly mutated human 
malignancies, challenging identification of driver mutations and targeted therapies. Transcription factor 
NF-E2 p45-related factor 2 (Nrf2) orchestrates a cytoprotective inducible program, which counteracts 
the damaging effects of solar UV radiation, the main etiological factor in cSCC development. 
Downregulation of Kelch-like ECH-associated protein 1 (Keap1), a Cullin-3/Rbx1 ubiquitin ligase 
substrate adaptor protein, which mediates the ubiquitination and proteasomal degradation of Nrf2, 
has a strong protective effect in a preclinical model of cSCC. However, in addition to Nrf2, Keap1 
affects ubiquitination of other proteins in the carcinogenesis process, including proteins involved in 
inflammation and DNA damage repair. Here, we generated Keap1flox/flox SKH-1 hairless mice in which 
Nrf2 is disrupted (Keap1flox/flox/Nrf2−/−) and subjected them chronically to solar-simulated UV radiation. 
We found that the incidence, multiplicity and burden of cSCC that form in Keap1flox/flox/Nrf2−/− mice 
are much greater than in their Keap1flox/flox/Nrf2+/+ counterparts, establishing Nrf2 activation as the 
protection mediator. Our findings further imply that inhibition of Nrf2 globally, a strategy proposed for 
cancer treatment, is unlikely to be beneficial.
Cutaneous squamous cell carcinomas (cSCC) are among the most frequent and highly mutated human cancers, 
carrying one mutation per ~30,000 bp of coding sequence1. Such astonishingly high burden of genetic alterations 
presents a major challenge in identifying driver mutations and developing targeted therapies, highlighting the 
importance of cancer prevention strategies. Solar ultraviolet (UV) radiation, the most abundant carcinogen in 
our environment, is the main factor in the etiology of human cSCC2. Public awareness campaigns regarding gen-
eral sun avoidance have not shown significant benefits – indeed, the incidence of cSCC is steadily rising, and the 
development of new strategies for prevention against know risk factors are urgently needed.
In sun-exposed skin, UV radiation causes DNA damage, inflammation, and immunosuppression, which col-
lectively contribute to the development of cSCC2. Many of the damaging processes caused by solar UV radiation 
are counteracted by transcription factor NF-E2 p45-related factor 2 (Nrf2, gene name NFE2L2), which orches-
trates a broadly cytoprotective transcriptional program allowing adaptation and survival under conditions of 
electrophilic, oxidative, and inflammatory stress3–5. Under basal conditions, Nrf2 undergoes continuous ubiq-
uitination and proteasomal degradation, which is primarily mediated by Kelch-like ECH-associated protein 1 
(Keap1)6, a Cullin-3/Rbx1 ubiquitin ligase substrate adaptor protein7–9. Specific reactive cysteine residues within 
Keap1 serve as sensors for a variety of endogenous and exogenous sulfhydryl-reactive small molecules (termed 
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inducers)10,11, which inhibit the substrate adaptor function of Keap1, leading to Nrf2 activation, and have shown 
protective effects in numerous animal models of disease, including cSCC12,13.
We have recently developed a mouse model of solar-simulated UV (SSUV) radiation-induced cSCC, in which 
the murine tumors closely resemble the histopathological spectrum of human cSCC13. In this model, the inci-
dence, multiplicity and burden of cSCCs that form in SKH-1 hairless mice, in which Nrf2 is genetically consti-
tutively activated by downregulation of Keap1 (Keap1flox/flox), are lower than those that arise in their wild-type 
counterparts13. Keap1flox/flox mice have two floxed alleles of the keap1 gene, which reduces its expression and 
consequently increases the levels of Nrf2 and its downstream target genes13,14, suggesting that the protective effect 
of Keap1 downregulation against SSUV skin damage and photocarcinogenesis are due to altered expression of 
Nrf2 target genes. However, alternative possibilities should be also considered. Thus, in addition to Nrf2, Keap1 
binds and promotes the ubiquitination and/or degradation of other proteins, such as Iκ B kinase β (IKKβ ), a 
protein kinase implicated in tumor development through activation of the nuclear factor (NF)-κ B pathway15. 
Moreover, Keap1 binds and mediates the ubiquitination of PALB216,17, leading to suppression of the assembly 
of the BRCA1-PALB2-BRCA2 protein complex, which plays a key role in DNA double strand break repair by 
homologous recombination17. Thus, it was important to ask whether or not Nrf2 is the mediator of the protec-
tive effect of the Keap1 downregulation that was observed in the SSUV-induced skin carcinogenesis model. To 
answer this question, we generated Keap1flox/flox SKH-1 hairless mice in which Nrf2 was disrupted (Keap1flox/flox/
Nrf2−/− SKH-1 hairless mice). We found that loss of Nrf2 completely abrogates the protective effect of Keap1 
downregulation, thus establishing Nrf2 activation as the mediator of protection in this preclinical model. Taken 
together with previous reports on the chemopreventive effects of pharmacological activators of Nrf2 against skin 
photodamage and photocarcinogenesis, our findings imply that mild Nrf2 activation is an effective strategy for 
protection against SSUV radiation-induced cSCC.
Materials and Methods
Animals. The animal experiments were performed according to the regulations described in the UK Animals 
(Scientific Procedures) Act 1986 and in strict compliance with institutional guidelines. The animal study plan was 
developed after ethical approval (Project Licence 60/5986), and was further approved by the Named Veterinary 
Surgeon and the Director of Biological Services of the University of Dundee. Keap1flox/flox SKH-1 hairless mice, 
in which Nrf2 is disrupted (i.e., Keap1flox/flox/Nrf2−/−), were generated by crossing Keap1flox/flox/Nrf2+/+ and 
Keap1+/+/Nrf2−/− mice, both on the SKH-1 hairless genetic background13. The mice were bred and maintained in 
our facility with free access to water and food (pelleted RM1 diet from SDS Ltd., Witham, Essex, UK), on a 12-h 
light/ 12-h dark cycle, 35% humidity. All experimental animals were age-matched and female. For biochemical 
analysis, the mice were euthanized, their dorsal skin was harvested, and immediately frozen in liquid N2. Frozen 
skin was pulverized into powder under liquid N2, and stored at − 80 °C until analysis.
Immunoblotting. Pulverized skin powder (~30 mg) was resuspended and homogenized in ice-cold radioim-
munoprecipitation assay buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1% NP-40; 0.5% sodium deoxycholate; 
0.1% sodium dodecyl sulfate; 1 mM ethylenediaminetetraacetic acid [EDTA]), containing protease inhibitors 
(Roche). The samples were mixed with LDS loading buffer (Invitrogen), loaded (35 μ g of protein/lane) on gradi-
ent (4–12%) Bis-Tris NuPAGE gel, and run under reducing condition using MOPS running buffer, with SeeBlue 
pre-stained molecular weight markers (Invitrogen) for size reference. The separated proteins were electrophoret-
ically transferred to a nitrocellulose membrane (Amersham Protran 0.45 NC). The membrane was then cut into 
three parts: the top part was probed for Nrf2, the middle part, for Keap1, and the bottom part, for β -actin. Parallel 
samples were processed in an identical way for detection of PALB2 levels, but the membrane was cut into two 
parts: the top part was probed for PALB2, and the bottom part, for β -actin. After blocking with 5% non-fat milk 
at 4 °C for 2 h, immunoblotting was performed using the following antibodies: anti-Nrf2 (rabbit monoclonal, 
1:1000 dilution, Cell Signaling), anti-Keap1 (rabbit polyclonal, 1:2000 dilution, a kind gift from John D. Hayes, 
University of Dundee18), or anti-PALB2 (rabbit polyclonal, 1:1000 dilution, Sigma-Aldrich Co.). The immunoblot 
for β -actin (Sigma–Aldrich Co., 1:10000 dilution) served as a loading control.
Enzyme activity assays. Pulverized skin powder (~30 mg) was resuspended in ice-cold phosphate buffer 
(100 mM potassium phosphate, pH 7.4; 100 mM KCl; 0.1 mM EDTA), and homogenized in an ice bath. The 
insoluble material was removed by centrifugation at 4 °C at 15,000 × g for 10 min. The supernatant fractions were 
used to determine the enzyme activities of NAD(P)H:quinone oxidoreductase 1 (NQO1) using menadione as a 
substrate19 and of glutathione S-transferase (GST) using 1-chloro-2,4-dinitrobenzene (CDNB) as a substrate20. 
The bicinchoninic acid (BCA) assay (Thermo Scientific) was employed to measure the protein concentration in 
each supernatant fraction, which was used to calculate the specific enzyme activity.
Quantitative real-time PCR. RNA was extracted from pulverized skin powder using RNeasy Fibrous 
Tissue Kit (Qiagen Ltd.). RNA (500 ng) was reverse transcribed into cDNA using Omniscript RT Kit (Qiagen 
Ltd.). The mRNA levels for Keap1 were determined by quantitative real-time PCR on a Perkin Elmer/Applied 
Biosystems Prism Model 7700 Sequence Detector instrument using primers and probe (TaqMan® Gene 
Expression Assays) purchased from Life Technologies. The TaqMan data for the mRNA species were normalized 
using β -actin (mouse ACTB, 4352933E) as an internal control.
Cutaneous carcinogenesis. The animals were individually marked and housed in such a way that every 
cage contained representatives of each genotype. Cutaneous carcinogenesis was initiated when the mice were 
8-week old by subjecting the animals chronically twice a week (on Tuesdays and Fridays) for 15 weeks to SSUV 
radiation (comprised of 2 J/cm2 UVA and 90 mJ/cm2 UVB). The irradiation unit (Daavlin, Bryan, OH) was 
equipped with an electrical fan to prevent excessive heating. For exposure to UV radiation, the animals were 
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placed in clear, bedding-free cages. SSUV radiation was provided by UVA340 lamps (Q-Lab, Germany), which 
simulate the solar UV radiation in the critical short wavelength region, from 365 nm to the solar cutoff of 295 nm, 
and have a peak emission at 340 nm. A UVB Daavlin Flex Control Integrating Dosimeter was used to quantify the 
radiant dose. The dose was confirmed by use of an external radiometer (X-96 Irradiance Meter; Daavlin, Bryan, 
OH) before and after each irradiation session. Tumors (defined as lesions ≥1 mm in diameter) were recorded 
once a week. To calculate the tumor volumes (v = 4π r3/3), the height, length, and width of each tumor were meas-
ured, and the average of the three measurements was used as the diameter.
Statistical analysis. Statistical analyses were performed using either Excel (Microsoft Corp.) or Stata 11.2 
(Statacorp, College Station, TX, USA). Values are means ± 1 S.D. or 1 S.E.M., as indicated in the figure legends.
Results and Discussion
We generated Keap1flox/flox SKH-1 hairless mice in which Nrf2 was disrupted (i.e., Keap1flox/flox/Nrf2−/−) by cross-
ing Keap1flox/flox/Nrf2+/+ and Keap1+/+/Nrf2−/− mice, both on the SKH-1 hairless genetic background (Fig. 1A). 
The Keap1flox/flox mice were originally developed to allow for generating tissue-specific Keap1−/− mice, but were 
found to have lower expression of Keap1 (i.e., hypomorphic keap1 alleles) and consequently, increased levels of 
Nrf2 and expression of its target genes in all tissues13,14. Thus, the Keap1flox/flox mice represent a genetic animal 
model for global constitutive Nrf2 activation to levels which are comparable to the levels that can be achieved by 
administration of small-molecule pharmacological Nrf2 activators.
Consistent with previous observations, the cutaneous mRNA levels for Keap1 are comparable in wild-type 
(Keap1+/+/Nrf2+/+) and Nrf2-knockout (Keap1+/+/Nrf2−/−) mice, but these levels are reduced by 70% in Keap1flox/flox/ 
Nrf2+/+ (p < 0.01) and Keap1flox/flox /Nrf2−/− (p < 0.01) mice (Fig. 1B). The differences in the Keap1 mRNA lev-
els among the four genotypes are in agreement with the differences in the corresponding protein levels, which 
are ~60% lower in Keap1flox/flox/Nrf2+/+ and Keap1flox/flox /Nrf2−/− mice in comparison with Keap1+/+/Nrf2+/+ 
and Keap1+/+/Nrf2−/− animals (Fig. 1C). As expected, Keap1flox/flox/Nrf2−/− mice have no detectable Nrf2 protein 
levels in their skin, whereas the presence of the transcription factor is readily detectable in skin isolated from 
Keap1flox/flox/Nrf2+/+ animals (Fig. 1C). In contrast to the increased protein levels of Nrf2 in Keap1flox/flox/Nrf2+/+ 
mice in comparison with Keap1+/+/Nrf2+/+ animals, there were no consistent differences among the genotypes in 
the levels of PALB2 (Fig. 1C), a protein which functions in homologous recombination. This is in agreement with 
the reported role of Keap1 in mediating the ubiquitination, but not the degradation of PALB216,17. In concordance 
with the differences in the Nrf2 levels between the Keap1flox/flox/Nrf2+/+ and Keap1flox/flox/Nrf2−/− genotypes, the 
Figure 1. Levels of Nrf2 and Keap1 in the skin of female Keap1flox/flox/Nrf2+/+ and Keap1flox/flox/Nrf2−/− 
SKH-1 hairless mice. (A) Breeding scheme used to generate Keap1flox/flox/Nrf2+/+ and Keap1flox/flox/Nrf2−/− 
SKH-1 hairless mice. (B) RNA was extracted from pulverized powder obtained from skin samples isolated 
from mice (female, 12–15-week-old, n = 3) of each of the four genotypes. After reverse transcription into 
cDNA, the mRNA levels for Keap1 were determined by quantitative real-time PCR using β -actin as an internal 
control. Statistical analysis was performed using Excel (Microsoft). The differences between groups were 
determined by Student’s t test. Values are means ± 1 S.D. Each mutant genotype was compared to the wild-type 
(Keap1+/+/Nrf2+/+) genotype. ns, non-significant; *p < 0.01. (C) Pulverized murine skin powder (~30 mg) was 
homogenized, and proteins (35 μ g) were separated by electrophoresis, transferred to nitrocellulose membrane, 
and probed for Nrf2, Keap1, PALB2, and β -actin. Each lane represents a sample from an individual 12-week-old 
female mouse of the indicated genotype. The full-size blots are shown in Supplementary Fig. 1.
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specific activity of the Nrf2-dependent enzymes NAD(P)H:quinone oxidoreductase 1 (NQO1) (Fig. 2A) and 
glutathione S-transferase (GST) (Fig. 2B) are lower in Keap1flox/flox/Nrf2−/− compared to Keap1flox/flox/Nrf2+/+ skin 
by 70% (p < 0.001) and 55% (p < 0.001), respectively.
Having established the differences in Nrf2 and the expression of its downstream target genes between the two 
mouse lines, we subjected groups of 30 mice of each genotype to chronic sub-erythemal doses of SSUV radiation, 
twice a week for 15 weeks. The development of cSCC was monitored during the subsequent 23 weeks. Consistent 
with our previous report13, the Keap1flox/flox/Nrf2+/+ mice were remarkably protected against the carcinogenic 
effects of SSUV radiation, and only 40% of the animals had skin lesions ≥ 1 mm in diameter at termination of 
the experiment (23 weeks after the SSUV radiation schedule was discontinued) (Fig. 3A). The protective effect of 
Keap1 downregulation was completely lost in the absence of Nrf2, and 100% of the Keap1flox/flox/Nrf2−/− mice had 
tumors at that time point, with 50% of them developing their first tumor at week 10 after receiving the last dose 
of SSUV radiation.
Kaplan–Meier ‘survival analysis’ applied to freedom-from-tumors, followed by a stratified log-rank test 
for equality of survivor function showed a highly significant difference between the Keap1flox/flox/Nrf2+/+ and 
Keap1flox/flox/Nrf2−/− groups (χ 2 = 14.5; p < 0.0001). The effect of the loss of functional Nrf2 on tumor multiplicity 
was also evident, and there was a ~5-fold increase, from 0.9 tumors per mouse in the Keap1flox/flox/Nrf2+/+ group 
to 4.6 tumors per mouse in the Keap1flox/flox/Nrf2−/− group (Fig. 3B). The difference between the two groups was 
Figure 2. Cutaneous enzyme activity of the Nrf2 transcriptional targets NQO1 and GST. Pulverized murine 
skin powder (~30 mg) obtained from skin samples isolated from animals (female, 12–15-week-old, n = 3) of 
each of the four genotypes was resuspended in ice-cold potassium phosphate buffer, homogenized in an ice 
bath, and subjected to centrifugation at 4 °C (15,000 x g for 10 min). The specific enzyme activities of NQO1 
(with menadione as a substrate) (A) and GST (CDNB as a substrate) (B) were determined in supernatant 
fractions. Statistical analysis was performed using Excel (Microsoft). The differences between groups were 
determined by Student’s t test. Values are means ± 1 S.D. *p < 0.001.
Figure 3. Loss of Nrf2 abrogates the protective effect of Keap1 downregulation against cutaneous 
carcinogenesis mediated by SSUV radiation. Female Keap1flox/flox/Nrf2+/+ and Keap1flox/flox/Nrf2−/− SKH-1 
hairless mice (n = 30, with every cage housing representatives of each genotype) were exposed chronically to 
SSUV radiation (comprised of 2 J/cm2 UVA and 90 mJ/cm2 UVB) beginning at 8 weeks of age, twice a week for 
15 weeks. During the subsequent 23 weeks after the end of the irradiation schedule, the appearance of tumors 
was monitored weekly, and lesions ≥ 1 mm in diameter were mapped, counted, and their volumes determined. 
The graphs show: tumor incidence (the number of mice with tumors) (A), multiplicity (the number of tumors 
per mouse) (B), and the total tumor burden (the sum of the volumes of all tumors per mouse) (C), all expressed 
as average values ± S.E.M. based on the total number of animals at risk. Statistical analysis was performed using 
Stata 11.2 (Statacorp, College Station, TX, USA).
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highly significant by ANOVA followed by Bartlett’s test for equal variances (F 179, p < 0.0001). The Keap1flox/flox/
Nrf2−/− group became significantly different from the Keap1flox/flox/Nrf2+/+ group by week six post-SSUV radi-
ation. In addition to the differences in tumor incidence and multiplicity, the tumor volume (expressed in mm3) 
per mouse was also profoundly affected by the genotype (Fig. 3C), and there was a remarkable ~30–150-fold 
difference in the total tumor burden between the Keap1flox/flox/Nrf2−/− and the Keap1flox/flox/Nrf2+/+ groups over 
the last 9 weeks of the experiment (i.e., weeks 14–23 post-SSUV) (F 21.7, p < 0.0001 by ANOVA with the Scheffe 
multiple comparison test).
The results from the current study clearly establish that the protective effect of downregulation of Keap1 in 
the SSUV-mediated cSCC mouse model is due to activation of Nrf2 and encourage the continued development 
of pharmacologic activators of Nrf2 as chemopreventive agents against photodamage and photocarcinogenesis. 
Importantly, the magnitude of Nrf2 activation in the Keap1flox/flox/Nrf2+/+ mice is relatively modest (~2-fold) 
and comparable to the degree of activation of the transcription factor by pharmacological agents in the skin of 
mice and humans13,21,22, and neither the Keap1flox/flox/Nrf2+/+ nor the Keap1flox/flox/Nrf2−/− mice had any obvious 
skin abnormalities. This is in contrast to transgenic mice expressing keratinocyte-specific constitutively active 
mutant Nrf2 under the control of a β -actin promoter and a CMV enhancer, in which the magnitude of upreg-
ulation of Nrf2 target genes is more than 10-fold (and for some genes, even approaching 100-fold), and which 
display sebaceous gland hypertrophy, hyperkeratosis and cyst formation23. The critical importance for cancer 
prevention by a mild (as opposed to robust) degree of activation of Nrf2 is evidenced by an increasing number 
of studies from several independent groups of investigators. Thus, it has been shown that keratinocyte-specific 
robust constitutive activation of Nrf2, which lacks the Keap1-binding domain, promotes HPV8-induced skin 
papilloma formation in mice24, whereas mild pharmacological activation is protective against skin photodamage 
and photocarcinogenesis13,22,25.
This notion is further supported by the seemingly paradoxical findings that, contrary to its role in cancer 
prevention, Nrf2 is frequently activated in established human tumors, and contributes to resistance to chemo-
therapy and radiation therapy. A comprehensive genomic characterization by the Cancer Genome Atlas Research 
Network has identified mutations in NRF2, KEAP1, or CUL3 in 34% of 178 lung squamous cell carcinomas26. 
Under conditions of oncogenic stress, such as that during sustained activation of KRAS, BRAF, or PI3K-AKT 
signaling, activation of Nrf2 facilitates cell proliferation27,28. Notably, in all of these cases the levels of Nrf2 and 
its classical target genes are constitutively very high, in sharp contrast to the mild activation, which is observed 
under conditions of Keap1 downregulation or treatment with pharmacological inducers. Taken together, these 
findings imply that the magnitude and duration of Nrf2-mediated transcriptional responses are critical determi-
nants of the balance between the beneficial and detrimental consequences of Nrf2 activation.
Our results have additional implications for cancer prevention and treatment. Since the discovery of Nrf2, 
accumulating experimental evidence has clearly demonstrated that: (i) Nrf2-knockout mice are more susceptible 
than their wild-type counterparts to the toxic and carcinogenic effects of many agents29–31, (ii) mild genetic or 
pharmacological activation of Nrf2 is protective against tumor initiation13,29, and (iii) Nrf2 deletion increases 
cancer risk29,31. Based on these findings, the development of Nrf2 inducers is an attractive strategy for cancer 
prevention. This is especially important because many Nrf2 inducers, such as isothiocyanates, flavonoids, and 
carotenoids are phytochemicals present in edible plants and have been consumed for centuries as components 
of the human diet32–34. More recently however, because of the high level of Nrf2 activity in many human tumors, 
the development of Nrf2 inhibitors has been proposed as a strategy for cancer treatment. Whereas this approach 
has shown promise initially in animal models as exemplified by the quassinoid phytochemical, brusatol35, the 
interpretation of the inhibitory effects on tumor development in these models is complicated by the fact that, in 
addition to Nrf2, compounds such as brusatol have the ability to affect fundamental cellular processes, including 
global protein translation36. Several known environmental carcinogens, such as the food contaminant ochratoxin 
A, have been shown to inhibit Nrf237–39. Moreover, the antioxidants vitamin E and N-acetylcysteine, suppress 
the activity of Nrf2 whilst promoting tumor development and metastasis40,41. Together with the results from our 
study, these findings imply that inhibition of Nrf2 globally is unlikely to be beneficial.
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